VIEMED HEALTHCARE, INC. (VMD) Scorecard
- 2026-Q2: Total return Win; Revenue growth Win; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth Win; EPS growth Lose.
- 2025-Q4: Total return Win; Revenue growth Win; EPS growth Win.
- 2025-Q3: Total return Lose; Revenue growth Win; EPS growth Win.
52/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 9 wins, 3 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q22/3 |
WinVMD / S&P 23.78% / 15.20% |
WinVMD / S&P 25.21% / 15.00% |
LoseVMD / S&P 2.86% / 50.40% |
| 2026-Q12/3 |
WinVMD / S&P 23.96% / -4.33% |
WinVMD / S&P 23.10% / 11.30% |
LoseVMD / S&P 19.35% / 27.70% |
| 2025-Q43/3 |
WinVMD / S&P 9.43% / 2.65% |
WinVMD / S&P 20.52% / 9.00% |
WinVMD / S&P 27.59% / 13.40% |
| 2025-Q32/3 |
LoseVMD / S&P -1.74% / 8.12% |
WinVMD / S&P 18.90% / 4.61% |
WinVMD / S&P 30.77% / 13.45% |
| 2025-Q22/3 |
LoseVMD / S&P -5.08% / 10.94% |
WinVMD / S&P 17.11% / 4.83% |
WinVMD / S&P 52.17% / 10.63% |
| 2025-Q12/3 |
LoseVMD / S&P -9.23% / -4.27% |
WinVMD / S&P 19.97% / 4.98% |
WinVMD / S&P 24.00% / 10.57% |
| 2024-Q43/3 |
WinVMD / S&P 9.41% / 2.41% |
WinVMD / S&P 22.54% / 5.25% |
WinVMD / S&P 16.00% / 6.15% |
| 2024-Q33/3 |
WinVMD / S&P 11.91% / 5.89% |
WinVMD / S&P 26.22% / 5.89% |
WinVMD / S&P 8.33% / 6.11% |
| 2024-Q22/3 |
LoseVMD / S&P -30.54% / 4.28% |
WinVMD / S&P 31.75% / 5.38% |
WinVMD / S&P 15.00% / 5.12% |
| 2024-Q13/3 |
WinVMD / S&P 20.13% / 10.56% |
WinVMD / S&P 32.79% / 5.71% |
WinVMD / S&P 56.25% / 5.59% |
| 2023-Q43/3 |
WinVMD / S&P 16.64% / 11.69% |
WinVMD / S&P 31.82% / 6.81% |
WinVMD / S&P 56.25% / 7.78% |
| 2023-Q32/3 |
LoseVMD / S&P -31.19% / -3.27% |
WinVMD / S&P 27.38% / 7.52% |
WinVMD / S&P 26.32% / -5.03% |
| 2023-Q22/3 |
LoseVMD / S&P 1.24% / 8.74% |
WinVMD / S&P 23.12% / 9.50% |
WinVMD / S&P 0.00% / -8.57% |
| 2023-Q12/3 |
WinVMD / S&P 27.78% / 7.50% |
WinVMD / S&P 20.87% / 10.77% |
LoseVMD / S&P -27.27% / -15.69% |
| 2022-Q42/3 |
WinVMD / S&P 26.00% / 7.56% |
WinVMD / S&P 18.60% / 11.88% |
LoseVMD / S&P -27.27% / -17.99% |
| 2022-Q32/3 |
WinVMD / S&P 11.52% / -4.88% |
WinVMD / S&P 14.60% / 13.47% |
LoseVMD / S&P -20.83% / -1.41% |
| 2022-Q21/3 |
WinVMD / S&P 8.03% / -16.10% |
LoseVMD / S&P 5.27% / 13.71% |
LoseVMD / S&P -25.93% / 11.04% |
| 2022-Q11/3 |
WinVMD / S&P -4.60% / -4.60% |
LoseVMD / S&P -11.05% / 15.97% |
LoseVMD / S&P -69.01% / 42.23% |
| 2021-Q40/3 |
LoseVMD / S&P -5.95% / 11.03% |
LoseVMD / S&P -10.85% / 15.00% |
LoseVMD / S&P -71.79% / 96.40% |
| 2021-Q30/3 |
LoseVMD / S&P -22.38% / 0.58% |
LoseVMD / S&P -4.32% / 10.77% |
LoseVMD / S&P -66.67% / 69.42% |
| 2021-Q21/3 |
LoseVMD / S&P -29.35% / 8.55% |
WinVMD / S&P 11.05% / 6.58% |
LoseVMD / S&P -62.50% / 51.81% |
| 2021-Q13/3 |
WinVMD / S&P 30.41% / 6.17% |
WinVMD / S&P 58.14% / -1.06% |
WinVMD / S&P 162.96% / 7.39% |
| 2020-Q42/3 |
LoseVMD / S&P -10.19% / 12.15% |
WinVMD / S&P 63.61% / -3.72% |
WinVMD / S&P 271.43% / -33.42% |
| 2020-Q32/3 |
LoseVMD / S&P -10.00% / 8.93% |
WinVMD / S&P 58.92% / -2.04% |
WinVMD / S&P 242.86% / -27.10% |
| 2020-Q23/3 |
WinVMD / S&P 101.68% / 20.54% |
WinVMD / S&P 48.02% / -0.46% |
WinVMD / S&P 260.00% / -27.11% |
| 2020-Q12/3 |
LoseVMD / S&P -23.23% / -19.60% |
WinVMD / S&P 25.53% / 3.47% |
WinVMD / S&P 17.39% / -14.75% |
| 2019-Q40/3 |
LoseVMD / S&P -10.40% / 9.07% |
LoseVMD / S&P VMD unavailable / 5.36% |
LoseVMD / S&P VMD unavailable / 2.99% |
| 2019-Q30/3 |
LoseVMD / S&P VMD unavailable / 1.70% |
LoseVMD / S&P VMD unavailable / 5.02% |
LoseVMD / S&P VMD unavailable / 0.21% |
| 2019-Q20/3 |
LoseVMD / S&P VMD unavailable / 4.30% |
LoseVMD / S&P VMD unavailable / 6.64% |
LoseVMD / S&P VMD unavailable / 8.65% |
| 2019-Q10/3 |
LoseVMD / S&P VMD unavailable / 13.65% |
LoseVMD / S&P VMD unavailable / 8.12% |
LoseVMD / S&P VMD unavailable / 14.29% |
| 2018-Q40/3 |
LoseVMD / S&P VMD unavailable / -13.52% |
LoseVMD / S&P VMD unavailable / 9.05% |
LoseVMD / S&P VMD unavailable / 18.23% |
| 2018-Q30/3 |
LoseVMD / S&P VMD unavailable / 7.71% |
LoseVMD / S&P VMD unavailable / 10.21% |
LoseVMD / S&P VMD unavailable / 19.06% |
| 2018-Q20/3 |
LoseVMD / S&P VMD unavailable / 3.43% |
LoseVMD / S&P VMD unavailable / 9.03% |
LoseVMD / S&P VMD unavailable / 14.46% |
| 2018-Q10/3 |
LoseVMD / S&P VMD unavailable / -0.76% |
LoseVMD / S&P VMD unavailable / 7.68% |
LoseVMD / S&P VMD unavailable / 12.46% |
| 2017-Q40/3 |
LoseVMD / S&P VMD unavailable / 6.64% |
LoseVMD / S&P VMD unavailable / 7.03% |
LoseVMD / S&P VMD unavailable / 13.82% |
| 2017-Q30/3 |
LoseVMD / S&P VMD unavailable / 4.48% |
LoseVMD / S&P VMD unavailable / 5.68% |
LoseVMD / S&P VMD unavailable / 17.57% |
| 2017-Q20/3 |
LoseVMD / S&P VMD unavailable / 3.09% |
LoseVMD / S&P VMD unavailable / 4.83% |
LoseVMD / S&P VMD unavailable / 17.74% |
| 2017-Q10/3 |
LoseVMD / S&P VMD unavailable / 6.07% |
LoseVMD / S&P VMD unavailable / 3.67% |
LoseVMD / S&P VMD unavailable / 13.32% |
| 2016-Q40/3 |
LoseVMD / S&P VMD unavailable / 3.82% |
LoseVMD / S&P VMD unavailable / 2.09% |
LoseVMD / S&P VMD unavailable / 7.05% |
| 2016-Q30/3 |
LoseVMD / S&P VMD unavailable / 3.85% |
LoseVMD / S&P VMD unavailable / 0.20% |
LoseVMD / S&P VMD unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | VMD total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 22.25% | 20.78% |
| Annualized return | 22.25% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | VMD total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 42.34% | 83.14% |
| Annualized return | 7.32% | 12.86% |
10Y · 2019-08-09 to 2026-08-27
| Metric | VMD total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 28.35% | 319.30% |
| Annualized return | 2.53% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Park Dental Partners, Inc. (PARK) | United States | $0.094B | |
| BioRestorative Therapies, Inc. (BRTX) | United States | $0.064B | |
| CRYO CELL INTERNATIONAL INC (CCEL) | United States | $0.033B | -11.02 |
| MANGOCEUTICALS, INC. (MGRX) | United States | $0.010B | -0.43 |
| agilon health, inc. (AGL) | United States | $1.272B | -7.76 |
| Progyny, Inc. (PGNY) | United States | $1.994B | 28.37 |
| Sotera Health Co (SHC) | United States | $5.271B | 30.96 |
| DAVITA INC. (DVA) | United States | $11.147B | 16.80 |